DOCSLIB.ORG

Role of Gonadotropin-Releasing Hormone Analogues in Metastatic

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Role of Gonadotropin-Releasing Hormone Analogues in Metastatic Di Lauro et al. Journal of Hematology & Oncology (2015) 8:53 DOI 10.1186/s13045-015-0147-z JOURNAL OF HEMATOLOGY & ONCOLOGY RESEARCH ARTICLE Open Access Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis Luigi Di Lauro1, Laura Pizzuti1, Maddalena Barba1,2, Domenico Sergi1, Isabella Sperduti3, Marcella Mottolese4, Carla Azzurra Amoreo4, Franca Belli5, Patrizia Vici1, Valerie Speirs6, Daniele Santini7, Ruggero De Maria2 and Marcello Maugeri-Saccà1,2* Abstract Background: Male breast cancer is a rare malignancy. Despite the lack of prospectively generated data from trials in either the adjuvant or metastatic setting, patients are commonly treated with hormone therapies. Much controversy exists over the use of gonadotropin-releasing hormone analogues in metastatic male breast cancer patients. We conducted this study to provide more concrete ground on the use of gonadotropin-releasing hormone analogues in this setting. Methods: We herein present results from a pooled analysis including 60 metastatic male breast cancer patients treated with either an aromatase inhibitor or cyproterone acetate as a monotherapy (23 patients) or combined with a gonadotropin-releasing hormone analogue (37 patients). Results: Overall response rate was 43.5 % in patients treated with monotherapy and 51.3 % with combination therapy (p = 0.6). Survival outcomes favored combination therapy in terms of median progression-free survival (11.6 months versus 6 months; p = 0.05), 1-year progression-free survival rate (43.2 % versus 21.7 %; p = 0.05), median overall survival (29.7 months versus 22 months; p = 0.05), and 2-year survival rate (64.9 % versus 43.5 %; p =0.05). Conclusions: In metastatic male breast cancer patients, the combined use of gonadotropin-releasing hormone analogues and aromatase inhibitors or antiandrogens seems to be associated with greater efficacy, particularly in terms of survival outcomes, compared with monotherapy. Collectively, these results encourage considering these agents in the metastatic setting. Keywords: Male breast cancer, Metastatic disease, Gonadotropin-releasing hormone analogue, Aromatase inhibitors, Cyproterone acetate Background that 92 % of MBC cases were estrogen receptor-positive Male breast cancer (MBC) is an uncommon malignancy [4]. Thus, antiestrogen therapy currently represents the accounting for less than 1 % of all breast cancer (BC) mainstay of treatment for these patients, even though cases [1], albeit its incidence is rising [2]. The hormone- the use of tamoxifen [5], aromatase inhibitors (AIs) driven nature of the disease was postulated in the 1940s [6–8], and fulvestrant [9, 10] was investigated only retro- [2] and corroborated over the past decades by studies spectively in small-sized cohorts. A therapeutic role for reporting on hormone receptor expression [3, 4]. Results the androgen receptor (AR) was also envisioned [11–13] from the National Cancer Institute’s Surveillance, Epi- and corroborated by immunohistochemical analysis and demiology, and End Results (SEER) database revealed gene-expression-profiling studies [3, 14]. Analysis of a large MBC cohort documented AR immunoreactivity in * Correspondence: [email protected] 64 % of cases [3], and over-expression of AR-related 1Division of Medical Oncology B, “Regina Elena” National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy pathway components was reported [14]. 2Scientific Direction, “Regina Elena” National Cancer Institute, Via Elio Chianesi Despite the wealth of hormonal treatments that have 53, 00144 Rome, Italy entered the therapeutic arena, owing to the rarity of this Full list of author information is available at the end of the article © 2015 Di Lauro et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Di Lauro et al. Journal of Hematology & Oncology (2015) 8:53 Page 2 of 5 disease and lack of prospectively generated data, a num- Patients’ characteristics are illustrated in Table 1. As ber of unsolved questions afflict daily clinical practice. A showninTable1,thegroupscompareddidnotdifferby heated argument surrounds the question of whether any of the variables considered. Overall, 37 patients re- gonadotropin-releasing hormone analogues (GnRH ana- ceived GnRH analogue-containing therapy (22 patients logues) are worth being administered in combination with CPA and 15 patients with an AI), and 23 patients with other hormonal treatments acting on peripheral were treated with GnRH analogue-free therapy (14 patients targets [7, 8, 13]. This controversy was fuelled by the ad- with CPA and 9 patients with an AI). vent of AIs [15]. In males, AIs lead to increased levels of follicle-stimulating hormone (FSH), luteinising hormone (LH), and testosterone (T) [16–20]. This phenomenon Table 1 Association between clinical-pathological features and was observed in hypogonadal men and MBC patients treatment received (N = 60) [16–20]. For MBC patients, implications of increased T Characteristic With GnRH N (%) Without GnRH N (%) p value* levels are twofold: i) the counteraction of the block im- Age posed by AIs through an excess of substrate and ii) a dir- Median 64 63 0.79 ect stimulation of cancer cells equipped with the AR [21]. Range 24–82 29–76 Briefly, the inhibition of the hypothalamic-pituitary feed- back loop, with the correlated reduction of the substrate ECOG PS for aromatization, was the rationale for combining AIs Median 1 1 0.88 with GnRH analogues. A second, though underestimated, Range 0–20–2 association strategy relates to the use of GnRH analogues Hormone receptor with antiandrogens [12, 13]. Our group reported on the status antitumor activity of antiandrogens [11, 12], a finding we Positive 32 (86.5) 19 (82.6) 0.99 recently strengthened in a larger series where hints on the Negative 2 (5.5) 2 (8.7) existence of an association between AR expression and Unknown 3 (8) 2 (8.7) clinical outcomes were also provided [13]. In this case, the Adjuvant systemic use of antiandrogens with a GnRH analogue stemmed therapy from the need to neutralize testicular and adrenal andro- Yes 19 (51) 10 (43.5) 0.60 gens, theorizing analogies in terms of androgen depend- ency between MBC and prostate cancer [13]. Indeed, our No 18 (49) 13 (56.5) group already reported on the suppression of gonadotro- Prior therapy for metastatic disease pins together with T suppression to castration levels in MBC patients who received cyproterone acetate (CPA) Yes 9 (24) 7 (30.5) 0.99 with buserelin [12]. These effects were also observed, al- No 28 (76) 16 (69.5) though to a lower extent, with CPA monotherapy [11]. Subsequent lines of Therefore, there is a common theme underlying the use of CT GnRH analogue with antiandrogens and AIs, namely, achiev- Median 1 1 0.72 ing the deepest possible T suppression to directly or indir- Range 1–21–2 ectly deprive cancer cells of a source of oncogenic stimuli, in Subsequent lines of the latter case by preventing the conversion of androstene- HT dione to 17b-estradiol operated by the aromatase enzyme. Median 1 1 0.85 By evaluating metastatic MBC (mMBC) treated with an Range 1–31–3 AI or CPA [8, 13], administered alone or combined with a GnRH analogue, we previously noted some differences fa- Dominant disease site voring the association. Nevertheless, the relatively re- Viscera 24 (64.9) 14 (60.8) stricted number of patients analyzed hindered statistically Bone 9 (24.3) 8 (34.8) 0.98 significant comparisons. Prompted by this observation, we Soft-tissue 4 (10.8) 1 (4.4) herein present results from a pooled analysis of these stud- Number of disease ies, with the inclusion of five additional patients, in order sites to gain more insights into the efficacy of GnRH analogue- 1 11 (29.7) 10 (43.4) containing hormonal therapy in mMBC patients. 2 21 (56.7) 9 (39.1) 0.99 ≥ 3 5 (13.6) 4 (17.5) Results ECOG PS: Eastern Cooperative Oncology Group Performance Status; CT: Sixty men mostly treated in the first-line metastatic setting chemotherapy; HT: hormone therapy were included in the present analysis. *Fisher exact test Di Lauro et al. Journal of Hematology & Oncology (2015) 8:53 Page 3 of 5 Stage at diagnosis was I, II, III, and IV in 11 (18.3 %), treated with monotherapy (p = 0.05) (Fig. 1). One-year 20 (33.3 %), 21 (35 %), and 8 (13.4 %) patients, respect- progression-free survival (PFS) rate also favored combin- ively. Stage I–II at diagnosis was 48 % in the monother- ation (43.2 % versus 21.7 %; p =0.05).Medianoverallsur- apy group and 52 % in the combination group. Overall, vival (mOS) was 29.7 months with combination (95 % CI = 29 patients received adjuvant systemic therapy, 10 in the 20.4–39) and 22 months (95 % CI = 15.9–28.1) with mono- monotherapy group (43.5 %) and 19 in the combination therapy (p = 0.05) (Fig. 1). Two-year survival rate was group (51 %). In the adjuvant setting, ten patients were 64.9 % in the combination group versus 43.5 % in the treated with chemotherapy, ten patients with hormone monotherapy group (p = 0.05). therapy, and nine patients with both chemotherapy and hormone therapy. Adjuvant hormone therapy consisted of tamoxifen in all but one patient who received goserelin. Discussion Adjuvant chemotherapy consisted of cyclophosphamide, Evidence on the therapeutic role of GnRH analogue as a methotrexate, and 5-fluorouracil (CMF) in 11 patients; partner for other hormonal agents in mMBC are scat- 5-fluorouracil, doxorubicin, and cyclophosphamide or tered, gathered from case reports or small retrospective 5-fluorouracil, epirubicin, and cyclophosphamide (FAC or series, and overall inconsistent [7, 8, 13, 15].
Load more

Recommended publications
  • Human Chorionic Gonadotropin (HCG), a Polypeptide Hormone Produced by the Human
    45792G/Revised: April 2011 CHORIONIC GONADOTROPIN FOR INJECTION, USP DESCRIPTION: Human chorionic gonadotropin (HCG), a polypeptide hormone produced by the human placenta, is composed of an alpha and a beta sub-unit. The alpha sub-unit is essentially identical to the alpha sub-units of the human pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), as well as to the alpha sub-unit of human thyroid-stimulating hormone (TSH). The beta sub-units of these hormones differ in amino acid sequence. Chorionic gonadotropin is obtained from the human pregnancy urine. It is standardized by a biological assay procedure. Chorionic Gonadotropin for Injection, USP is available in multiple dose vials containing 10,000 USP Units with accompanying Bacteriostatic Water for Injection for reconstitution. When reconstituted with 10 mL of the accompanying diluent each vial contains: Chorionic gonadotropin 10,000 Units Mannitol 100 mg Benzyl alcohol 0.9% Water for Injection q.s. Buffered with dibasic sodium phosphate and monobasic sodium phosphate. Hydrochloric acid and/or sodium hydroxide may have been used for pH adjustment (6.0­ Reference ID: 2933198 8.0). Nitrogen gas is used in the freeze drying process. CLINICAL PHARMACOLOGY: The action of HCG is virtually identical to that of pituitary LH, although HCG appears to have a small degree of FSH activity as well. It stimulates production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce androgens and the corpus luteum of the ovary to produce progesterone. Androgen stimulation in the male leads to the development of secondary sex characteristics and may stimulate testicular descent when no anatomical impediment to descent is present.
    [Show full text]
  • Gonadotropin and Testosterone Measurements After
    Pediat. Res. 10: 46-51 (1976) Estradiol puberty estrogen sexual differentiation gonadotropins testosterone maturation Gonadotropin and Testosterone Measurements after Estrogen Administration to Adult Men, Prepubertal and Pubertal Boys, and Men with Hypogonadotropism: Evidence for Maturation of Positive Feedback in the Male HOWARD E. KULIN"" AND EDWARD 0. REITER Reproduction Research Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA Extract MATERIALS AND METHODS Nineteen male subjects were given five daily injections of SUBJECTS 17~-estradiol and circulating levels of estradiol (E 2 ), testosterone (T), and gonadotropins were determined by radioimmunoassay Seven normal, adult men (ages 20-22) and one male (age 21) before, during, and after the steroid course. Peak levels of E 2 with the syndrome of vanishing testes (I) were hospitalized for attained during the 5 days of treatment ranged from 173-577 pg/ml. study at the Clinical Center of the National Institutes of Health. Four of seven normal adult men and one castrate man demonstrated Each patient was given five daily intramuscular injections of IO or suppression of follicle-stimulating hormone ( FSH) and luteinizing 15 ,ug/kg body weight of 17~-estradiol (E2 ) (20) and blood samples hormone ( LH) with a subsequent rise in LH ( positive feedback) were obtained every 12-24 hr before, during, and after the estrogen while E 2 levels remained elevated. A rise in T was associated with course (see Table I). the LH increment in the four normal men. Nine pre-, early, or Nine endocrinologically normal boys between the ages of 7 and midpubertal boys and two men with hypogonadotropic hypogo­ 18 were studied in the course of evaluation for short stature, nadism displayed only gonadotropin suppression after E 2 adminis­ precocious puberty, or delayed adolescence.
    [Show full text]
  • Chorionic Gonadotropin Human (C0684)
    Chorionic gonadotropin human Product Number C 0684 Storage Temperature -0 °C Product Description When hCG was used in combination with recombinant CAS Number: 9002-61-3 interferon-γ, there was a significant cooperative pI = 2.951 induction of nitric oxide synthesis (iNOS) in a dose- Extinction Coefficient: E1% = 3.88 (278nm)2 dependent manner in mouse peritoneal macrophages Synonym: Choriogonin, hCG suggesting that hCG may provide a second signal for synergistic induction of NO synthesis.9 The molecular weight is approximately 37.9 kDa (with approximately 31% carbohydrate by weight). The Precautions and Disclaimer theoretical molecular weight is 37.9 kDa based on the For Laboratory Use Only. Not for drug, household or native form, which contains 2 subunits. The α subunit other uses. has a molecular weight of 14.9 kDa of which approximately 10.2 kDa is for the polypeptide and Preparation Instructions approximately 4.7 kDa for the carbohydrate. The hCG is soluble in water and aqueous buffers such β subunit has a molecular weight of 23 kDa of which phosphate buffer. hCG is also soluble in aqueous approximately 16.0 kDa is for the polypeptide and glycerol and glycols and is insoluble in ethanol.1 approximately 7.0 kDa is for the carbohydrate.3,4,5 Solutions should be sterile filtered and not autoclaved. Product Number C 0684 is sterile filtered and contains Storage/Stability approximately 1,000 I.U. per vial. Dilute aqueous solutions undergo rapid loss of activity when stored frozen, or heated, or if excess acid or hCG is a glycoprotein hormone produced by the base is added.
    [Show full text]
  • Advanced Prostate Cancer: Developing Gonadotropin- Releasing Hormone Analogues Guidance for Industry
    Advanced Prostate Cancer: Developing Gonadotropin- Releasing Hormone Analogues Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to https://www.regulations.gov. Submit written comments to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register. For questions regarding this draft document, contact Elaine Chang at 240-402-2628. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) July 2019 Clinical/Medical Advanced Prostate Cancer: Developing Gonadotropin- Releasing Hormone Analogues Guidance for Industry Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993-0002 Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353; Email: [email protected] https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
    [Show full text]
  • WSAVA List of Essential Medicines for Cats and Dogs
    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
    [Show full text]
  • The Effect of Gonadotropin Withdrawal and Stimulation with Human Chorionic Gonadotropin on Intratesticular Androstenedione and DHEA in Normal Men
    ORIGINAL ARTICLE Endocrine Research The Effect of Gonadotropin Withdrawal and Stimulation with Human Chorionic Gonadotropin on Intratesticular Androstenedione and DHEA in Normal Men M. Y. Roth, S. T. Page, K. Lin, B. D. Anawalt, A. M. Matsumoto, B. Marck, W. J. Bremner, and J. K. Amory Downloaded from https://academic.oup.com/jcem/article/96/4/1175/2720870 by guest on 02 October 2021 Departments of Internal Medicine (M.Y.R., S.T.P., B.D.A., A.M.M., W.J.B., J.K.A.) and Obstetrics and Gynecology (K.L.) and Center for Research in Reproduction and Contraception (M.Y.R., S.T.P., B.D.A., A.M.M., W.J.B., J.K.A.), University of Washington, Seattle, Washington 91895; and Geriatric Research (B.M.), Education and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, Washington 98105 Introduction: Concentrations of intratesticular (IT) testosterone (T) are known to be 100–200 times those of serum T; however, the IT concentrations of T’s precursors, their testicular to serum gra- dients, gonadotropin dependence, and response to stimulation with human chorionic gonado- tropin (hCG) have not been studied in detail. We hypothesized that serum and IT androstenedione (ADD) and IT dehydroepiandrosterone (DHEA) would be significantly suppressed by the adminis- tration of a GnRH antagonist and increased when stimulated by hCG, without a similar suppression of serum DHEA. Methods: We suppressed gonadotropins in 23 normal men with the GnRH antagonist acyline and randomly assigned them to one of four doses of hCG, 0, 15, 60, or 125 IU sc every other day for 10 d.
    [Show full text]
  • Gonadotropin Releasing Hormone Test
    Paediatric & Adolescent Endocrinology Yorkshire Regional Centre Leeds Children’s Hospital Gonadotrophin Releasing Hormone (GnRH) test http://www.pathology.leedsth.nhs.uk/dnn_bilm/Investigationprotocols/Pituitaryprotocols/GnRHTest.aspx Indication To diagnose hypothalamic-pituitary disease in precocious and delayed puberty in both sexes in those children with low basal gonadotrophins. Contra-indications This test may be performed simultaneously with TRH or glucagon as part of triple pituitary test. Principle GnRH (gonadotrophin releasing hormone) is a decapeptide secreted by the hypothalamus which stimulates the production and secretion of LH and FSH by the anterior pituitary. Side effects GnRH may rarely cause nausea, headache and abdominal pain. Preparation No specific patient preparation is required. Requirements 3 plain tubes Drug administration: GnRH (Gonadorelin) 2.5 microgram/kg to a maximum of 100 microgram Procedure take 2 mL blood for LH & FSH and testosterone (males) and oestradiol time 0 min (females) immediately give GnRH IV as a bolus (dose as above) time 20 min take 2 mL blood for LH & FSH time 60 min take 2 mL blood for LH & FSH Interpretation 1. Normal basal reference values in prepubertal children are: LH < 2.0 IU/L FSH < 2.0 IU/L 2. Following GnRH, the response may be considered normal if the basal values are in the reference range and there is at least a doubling at 20 min for LH and FSH. The response varies throughout the menstrual cycle: early (D4) < late follicular (D11) = "luteal" (D21), max response occurs at the mid- cycle (D14). 3. An exaggerated response is seen in primary & secondary gonadal failure. 4.
    [Show full text]
  • Estrogen Dependence of a Gonadotropin-Induced Steroidogenic Lesion in Rat Testicular Leydig Cells
    Estrogen Dependence of a Gonadotropin-induced Steroidogenic Lesion in Rat Testicular Leydig Cells S. B. Cicorraga, … , K. J. Catt, M. L. Dufau J Clin Invest. 1980;65(3):699-705. https://doi.org/10.1172/JCI109716. Research Article Leydig cells isolated from the testes of rats treated with intravenous exogenous gonadotropin (hCG) or subcutaneous gonadotropin-releasing hormone (GnRH) show markedly decreased luteinizing hormone (LH) receptors and a partial block in testicular 17,20 desmolase activity. In contrast, Leydig cells from animals with equivalent degrees of LH receptor loss induced by subcutaneous hCG treatment show no change in 17,20 desmolase activity. These findings indicated that the acuteness of gonadotrophic stimulation, rather than the extent of LH receptor loss, was responsible for the steroidogenic lesion. A role of estradiol in the enzymatic block produced in vivo by acute elevation of circulating gonadotropin (intravenous hCG or GnRH-stimulated endogenous LH) was suggested by rapid elevations of testicular 17β- estradiol within 30 min after intravenous hCG, whereas more gradual increases in estradiol occurred 4-8 h after subcutaneous hCG. The inhibitory effect of endogenous estrogen on testicular steroidogenesis was confirmed by the ability of an estrogen antagonist (Tamoxifen) to prevent the reduction of testosterone responses caused by intravenous hCG and subcutaneous GnRH. In addition, Tamoxifen significantly increased the number of LH receptors in Leydig cells from both control and gonadotropin-desensitized animals. These findings indicate that the acute elevations of intratesticular estrogen produced by treatment with hCG or GnRH are responsible for the steroidogenic lesion seen in gonadotropin-desensitized Leydig cells. These results also suggest that locally produced estrogens […] Find the latest version: https://jci.me/109716/pdf Estrogen Dependence of a Gonadotropin-induced Steroidogenic Lesion in Rat Testicular Leydig Cells S.
    [Show full text]
  • Basal Serum Luteinizing Hormone Value As the Screening Biomarker in Female Central Precocious Puberty
    Original article https://doi.org/10.6065/apem.2019.24.3.164 Ann Pediatr Endocrinol Metab 2019;24:164-171 Basal serum luteinizing hormone value as the screening biomarker in female central precocious puberty Seung Heo, MD1, Purpose: Precocious puberty refers to the development of secondary sex Young Seok Lee, MD, PhD2, characteristics before ages 8 and 9 years in girls and boys, respectively. Central Jeesuk Yu, MD, PhD1 precocious puberty (CPP) is caused by premature activation of the hypothalamus- pituitary-gonadal (HPG) axis and causes thelarche in girls before the age of 8. A 1Department of Pediatrics, Dankook gonadotropin-releasing hormone (GnRH) stimulation test is the standard diagnostic University Hospital, Dankook University modality for diagnosing CPP. However, the test cannot always be used for screening College of Medicine, Cheonan, Korea because it is expensive and time-consuming. This study aimed to find alternative 2 Department of Diagnostic Radiology, reliable screening parameters to identify HPG axis activation in girls <8 years old Dankook University Hospital, Dankook (CPP) and for girls 8–9 years old (early puberty, EP). University College of Medicine, Methods: From January 2013 to June 2015, medical records from 196 girls younger Cheonan, Korea than 9 years old with onset of breast development were reviewed, including 126 girls who had a bone age (BA) 1 year above their chronological age. All patients underwent a GnRH stimulation test, and 117 underwent pelvic sonography. The girls were divided into 4 groups based on age and whether the GnRH stimulation test showed evidence of central puberty. Subanalyses were also conducted within each group based on peak luteinizing hormone (LH) level quartiles.
    [Show full text]
  • Follicle Stimulating Hormone (Fsh)
    Lab Dept: Chemistry Test Name: FOLLICLE STIMULATING HORMONE (FSH) General Information Lab Order Codes: FSH Synonyms: FSH; Follitropin CPT Codes: 83001 – Gonadotropin; follicle stimulating hormone Test Includes: Follicle stimulating hormone (FSH) concentration reported in mIU/mL. Logistics Test Indications: FSH is a glycoprotein hormone secreted by the anterior pituitary in response to gonadotropin-releasing hormone. FSH and LH play a critical role in maintaining the normal function of the male and female reproductive systems. Lab Testing Sections: Chemistry Phone Numbers: MIN Lab: 612-813-6280 STP Lab: 651-220-6550 Test Availability: Daily, 24 hours Turnaround Time: 1 day Special Instructions: N/A Specimen Specimen Type: Blood Container: Preferred: Green top (Li Heparin) tube Alternate: Red, marble or gold top tube Draw Volume: 1.5 mL (Minimum: 0.75 mL) blood Processed Volume: 0.5 mL (Minimum: 0.25 mL) plasma/serum Collection: Routine blood collection Special Processing: Lab Staff: Centrifuge specimen, remove plasma/serum aliquot into a plastic sample cup. Store at 2-8 degrees Centigrade for up to 7 days. Patient Preparation: None Sample Rejection: Mislabeled or unlabeled specimen Interpretive Reference Range: Age Reference Range (mIU/mL) Males < 1 year: 0.09 – 2.41 1 - <5 years: 0 – 0.91 5 - <10 years: 0 – 1.62 10 - <13 years: 0.35 – 3.91 13 - <19 years: 0.78 – 5.1 Adult: 0.95 – 11.95 Females <1 year: 0.38 – 10.4 1 - <9 years: 0.42 – 5.45 9 - <11 years: 0.44 – 4.22 11 - <19 years: 0.26 – 7.77 Menstruating Females Follicular Phase: 3.03 – 8.08 Midcycle Peak: 2.55 – 16.69 Luteal Phase: 1.38 – 5.47 Post-Menopausal: 26.72 – 133.4 Critical Values: N/A Limitations: Heterophile antibodies may interfere with immunoassay tests.
    [Show full text]
  • Gonadotropins)
    Fact Sheet From ReproductiveFacts.org The Patient Education Website of the American Society for Reproductive Medicine Side effects of injectable fertility drugs (gonadotropins) What are gonadotropins? IVF couples by freezing (cryopreserving) the embryos and Gonadotropins are fertility medications given by injection that transferring at a later date when the OHSS symptoms are contain follicle-stimulating hormone (FSH) alone or combined with completely resolved. luteinizing hormone (LH). During a regularly occurring menstrual • Multiple Gestation. When using injectable gonadotropins cycle, both FSH and LH are produced by the pituitary gland in the alone or with IUI, up to 30% of pregnancies are associated brain to naturally stimulate the ovaries to make a single egg each with multiple implantations (twins or more), which only month. When FSH (with or without LH) is given as an injection, occur in 1% to 2% of naturally occurring pregnancies. it works directly on the ovaries to make multiple follicles (cysts The increased risk of multiples is due to the number of containing eggs). Other fertility medications, such as clomiphene eggs that are stimulated during an ovulation induction citrate, stimulate the ovaries by working in conjunction with the cycle or due to the number of embryos transferred in an brain. IVF cycle. While most multiple pregnancies are twins, up to 5% are triplets or higher. When a woman has twins or How are these medications used? more, she is at higher risk of miscarriage, preterm delivery, Gonadotropins usually are used during fertility treatments such infant abnormalities, handicap due to the consequences as intrauterine insemination (IUI) or in vitro fertilization (IVF).
    [Show full text]
  • Advanced Control Specialty Formulary® Is a Guide Within Select Therapeutic Categories for Clients, Plan Members and Health Care Providers
    October 2021 ® Advanced Control Specialty Formulary The CVS Caremark® Advanced Control Specialty Formulary® is a guide within select therapeutic categories for clients, plan members and health care providers. Generics should be considered the first line of prescribing. If there is no generic available, there may be more than one brand-name medicine to treat a condition. These preferred brand-name medicines are listed to help identify products that are clinically appropriate and cost-effective. Generics listed in therapeutic categories are for representational purposes only. This is not an all-inclusive list. This list represents brand products in CAPS, branded generics in upper- and lowercase Italics, and generic products in lowercase italics. PLAN MEMBER HEALTH CARE PROVIDER Your benefit plan provides you with a prescription benefit program Your patient is covered under a prescription benefit plan administered administered by CVS Caremark. Ask your doctor to consider by CVS Caremark. As a way to help manage health care costs, prescribing, when medically appropriate, a preferred medicine from authorize generic substitution whenever possible. If you believe a this list. Take this list along when you or a covered family member brand-name product is necessary, consider prescribing a brand name sees a doctor. on this list. Please note: Please note: • Your specific prescription benefit plan design may not cover • Generics should be considered the first line of prescribing. certain products or categories, regardless of their appearance in • The member's prescription benefit plan design may alter coverage this document. Products recently approved by the U.S. Food and of certain products or vary copay amounts based on the condition Drug Administration (FDA) may not be covered upon release being treated.
    [Show full text]